List of Aptiom drug patents
Aptiom is owned by Sunovion Pharms Inc.
Aptiom contains Eslicarbazepine Acetate.
Aptiom has a total of 11 drug patents out of which 0 drug patents have expired.
Aptiom was authorised for market use on 08 November, 2013.
Aptiom is available in tablet;oral dosage forms.
Aptiom can be used as treatment of partial-onset seizures in patients with epilepsy who have been previously treated with oxcarbazepine, treatment of partial-onset seizures in a patient with refractory partial-onset seizures; treatment of partial-onset seizures, treatment of partial-onset seizures in a patient suffering from or susceptible to absence seizures; treatment of partial-onset seizures, treatment of partial-onset seizures; treatment of partial-onset seizures in a patient with refractory partial-onset seizures, treatment of partial-onset seizures.
The generics of Aptiom are possible to be released after 24 August, 2032.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9206135 | SUNOVION PHARMS INC | Asymmetric catalytic reduction of oxcarbazepine |
Apr, 2026
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11364247 | SUNOVION PHARMS INC | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(1 year, 10 months from now) | |
| US10702536 | SUNOVION PHARMS INC | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(1 year, 10 months from now) | |
| US10695354 | SUNOVION PHARMS INC | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(1 year, 10 months from now) | |
| US10675287 | SUNOVION PHARMS INC | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(1 year, 10 months from now) | |
| US9643929 | SUNOVION PHARMS INC | Asymmetric catalytic reduction of oxcarbazepine |
Apr, 2026
(2 years from now) | |
| US9763954 | SUNOVION PHARMS INC | Therapeutical uses of eslicarbazepine |
Sep, 2028
(5 years from now) | |
| US9566244 | SUNOVION PHARMS INC | Pharmaceutical composition comprising licarbazepine acetate |
Oct, 2028
(5 years from now) | |
| US10912781 | SUNOVION PHARMS INC | Pharmaceutical composition comprising licarbazepine acetate |
Oct, 2028
(5 years from now) | |
| US8372431 | SUNOVION PHARMS INC | Pharmaceutical composition comprising licarbazepine acetate |
Apr, 2030
(6 years from now) | |
| US9750747 | SUNOVION PHARMS INC | Treatments involving eslicarbazepine acetate or eslicarbazepine |
Aug, 2032
(9 years from now) | |
Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient
Market Authorisation Date: 08 November, 2013
Treatment: Treatment of partial-onset seizures; Treatment of partial-onset seizures in a patient with refractory partial-onset seizures; Treatment of partial-onset seizures in patients with epilepsy who have bee...
Dosage: TABLET;ORAL
APTIOM family patents
25
United States
7
Portugal
7
Japan
7
European Union
5
Korea, Republic of
5
Canada
5
Spain
5
Mexico
4
Australia
4
Russia
4
Argentina
4
Brazil
3
Denmark
3
Cyprus
3
Poland
3
United Kingdom
3
Slovenia
3
China
2
Croatia
2
New Zealand
2
Ukraine
2
South Africa
2
RS
2
Hungary
2
Lithuania
1
IB
1
Austria
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic